Reason.com - Free Minds and Free Markets
Reason logo Reason logo
  • Latest
  • Magazine
    • Current Issue
    • Archives
    • Subscribe
    • Crossword
  • Video
  • Podcasts
    • All Shows
    • The Reason Roundtable
    • The Reason Interview With Nick Gillespie
    • The Soho Forum Debates
    • Just Asking Questions
    • The Best of Reason Magazine
    • Why We Can't Have Nice Things
  • Volokh
  • Newsletters
  • Donate
    • Donate Online
    • Donate Crypto
    • Ways To Give To Reason Foundation
    • Torchbearer Society
    • Planned Giving
  • Subscribe
    • Reason Plus Subscription
    • Print Subscription
    • Gift Subscriptions
    • Subscriber Support

Login Form

Create new account
Forgot password

Science & Technology

Bringing Biohacking to the Masses Is Latest Aim of Andreessen Horowitz

The savvy venture capitalists at Andreessen Horowitz are now banking on "smart drug" startup Nootrobox.

Elizabeth Nolan Brown | 12.8.2015 8:35 AM

Share on FacebookShare on XShare on RedditShare by emailPrint friendly versionCopy page URL
Media Contact & Reprint Requests
Nootrobox/Facebook

Powerhouse venture-capital firm Andreessen Horowitz announced last week that it will invest $2 million in the "smart drug" start-up Nootrobox, which makes supplements aimed at improving focus, memory, and mental energy. Chris Dixon, the Andreessen Horowitz partner who led the investment, said he was interested by the company's goal of bringing "biohacking" to the masses. 

Other past recipients of the firm's funds include companies such as Buzzfeed, Skype, Twitter, Coinbase, Medium, Airbnb, Foursquare, Pinterest, Oculus VR, and Lyft.

Some background on the Nootrobox decision, from The New York Times:  

Nootrobox is in the business of nootropics, substances that might improve the way the mind works. The start-up's founders say they are part of the "biohacking" movement, which treats the human body as software that can be improved through constant tweaking.

It's an industry that has drawn enthusiasts from around the Internet, with groups on Reddit drawing tens of thousands of readers, as well as entrepreneurs like Dave Asprey of Bulletproof. It is that sense of movement and community that drew the interest of Chris Dixon…

With the Nootrobox investment, Andreessen Horowitz continues its recent embrace of biohacker-friendly start-ups, from uBiome (a company that makes affordable kits for consumers to sequence their microbiome) to the much-hyped meal-replacement drink Soylent. "We invest in technologists," Dixon told the Times, explaining that while many smart-drug companies "have been more infomercial-driven," Nootrobox is different.

Founded in 2014 by millennials Michael Brandt and Geoffrey Woo, the company claims to take a more scientific approach to nootropics than many of its competitors. "We use the precise ingredients at the right dosages and the right ratios as supported by double-blind, peer-reviewed clinicals," the Nootrobox website claims.

Thus far, Nootrobox has been both profitable and popular among the Silicon Valley crowd.

The company offers three nootropic "stacks," each a blend of allegedly brain-boosting substances. RISE—a blend of bacopa monnieri, rhodiola rosea, and ?-GPC—is the company's everyday nootropic, designed to be taken twice a day for enhanced "clarity and focus." SPRINT is meant to be taken for a quicker and more concentrated boost of brainpower; it contains caffeine, B vitamins, L-theanine, Glucuronolactone, and Inositol. The last stack—YAWN—is a sleep-aid composed of Melatonin, magnesium citrate, Glycine, and L-theanine. 

"We're not medical doctors nor biochemistry experts," Woo told Fusion, "but we are experts in building teams and building products. … we see ourselves as applying Silicon Valley aesthetics and operational know-how to the murky world of nootropics." And like Airbnb and Uber, Nootrobox is prepared for potential regulatory battles, Woo said.

As long as Nootrobox stacks rely on naturally occuring substances—herbs, vitamins, amino acids, etc.—that are "generally regarded as safe" by the FDA, it may be able to avoid a big one (although the empire-building FDA has had its designs on the supplement industry for a while). But man-made compounds for cognitive enhancement, such as Modafinil, are still getting the FDA side-eye, despite myriad studies showing safety and efficacy. 

"Modafinil may well deserve the title of the first well-validated pharmaceutical nootropic agent," declared European College of Neuropsychopharmacology President Guy Goodwin in August. "If correct, the present update means the ethical debate is real: how should we classify, condone or condemn a drug that improves human performance in the absence of pre-existing cognitive impairment?" 

For more on nootropics and biohacking, check out the Andreessen Horowitz podcast on smart drugs here, or see Reason's previous coverage of self-directed evolution, the domestication of biotechnology, transgenic art, college bans on smart drugs, Adderall panics, brain-preservation techniques, radical life extention, and transhumanist summer camps. 

Start your day with Reason. Get a daily brief of the most important stories and trends every weekday morning when you subscribe to Reason Roundup.

This field is for validation purposes and should be left unchanged.

NEXT: Ask No Questions

Elizabeth Nolan Brown is a senior editor at Reason.

Science & TechnologyBrainBiologyTechnologyMoney
Share on FacebookShare on XShare on RedditShare by emailPrint friendly versionCopy page URL
Media Contact & Reprint Requests

Show Comments (11)

Latest

Can Schools Ban This 'There Are Only Two Genders' Shirt? Supreme Court Declines To Hear Free Speech Case

Billy Binion | 5.28.2025 5:21 PM

RFK Jr. Denigrates Privately Funded Medical Research

Joe Lancaster | 5.28.2025 3:55 PM

Can Trump Yank Harvard's Remaining Federal Funding?

Emma Camp | 5.28.2025 3:30 PM

A Federal Judge Lists 8 Ways That Trump Violated the Constitution by Punishing a Disfavored Law Firm

Jacob Sullum | 5.28.2025 3:15 PM

Elon Musk Is Right. The 'Big Beautiful Bill' Is a Bad Deal.

Eric Boehm | 5.28.2025 1:00 PM

Recommended

  • About
  • Browse Topics
  • Events
  • Staff
  • Jobs
  • Donate
  • Advertise
  • Subscribe
  • Contact
  • Media
  • Shop
  • Amazon
Reason Facebook@reason on XReason InstagramReason TikTokReason YoutubeApple PodcastsReason on FlipboardReason RSS

© 2024 Reason Foundation | Accessibility | Privacy Policy | Terms Of Use

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

r

Do you care about free minds and free markets? Sign up to get the biggest stories from Reason in your inbox every afternoon.

This field is for validation purposes and should be left unchanged.

This modal will close in 10

Reason Plus

Special Offer!

  • Full digital edition access
  • No ads
  • Commenting privileges

Just $25 per year

Join Today!